Zusammenfassung
Während die Entwicklung von Autoantikörpern im Zusammenhang mit einer Therapie mit TNF-α-Antagonisten häufig ist, so entwickeln doch nur wenige Patienten einen durch diese Präparate induzierten klinisch manifesten Lupus erythematodes. Insbesondere bei Einsatz des vollhumanisierten TNF-Antagonisten Adalimumab scheinen diese kutanen unerwünschten Wirkungen deutlich seltener aufzutreten als bei anderen Präparaten. Wir berichten über eine Patientin mit rheumatoider Arthritis, bei der es 8 Monate nach Beginn einer Adalimumab-Therapie zu einem Lupus erythematodes tumidus an beiden Handrücken sowie zur Entwicklung von Antihiston-Antikörpern kam.
Abstract
Patients treated with TNF-α inhibitors frequently have serum autoantibodies, but only a few develop clinically apparent lupus erythematosus. The TNF-α inhibitor adalimumab is a fully humanized antibody and seems to induce autoantibodies less frequently than other drugs of this group. We report on a patient with rheumatoid arthritis, who developed anti-histone antibodies and lupus tumidus after eight months on adalimumab therapy.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Ramos-Casals M, Brito-Zerón P, Muñoz S et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86(4):242–251
De Bandt M, Sibilia J, Le Loët X et al (2005) Club rhumatismes et inflammation systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a french national survey. Arthritis Res Ther 7(3):R545–R551
Spillane AP, Xia Y, Sniezek PJ (2007) Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol 56 (5 Suppl):S114–S116
Sheth N, Greenblatt D, Patel S, Acland K (2007) Adalimumab-induced cutaneous lupus. Clin Exp Dermatol 32(5):593–594
Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381–387
Schiff MH, Burmester GR, Kent JD et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65(7):889–894
Carlson E, Rothfield N (2003) Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 48(4):1165–1166
Benucci M, Saviola G, Baiardi P et al (2008) Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 27(1):91–95
Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 16;359(9306):579–580
Bootsma H, Spronk PE, Hummel EJ et al (1996) Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 25(6):352–359
Lebwohl M, Bagel J, Gelfand JM et al (2008) From the medical board of the national psoriasis foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58(1):94–105
Kapetanovic MC, Larsson L, Truedsson L et al (2006) Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 8(4):R131
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sohl, S., Renner, R., Winter, U. et al. Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie. Hautarzt 60, 826–829 (2009). https://doi.org/10.1007/s00105-008-1699-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-008-1699-4